AIGH Capital Management’s Regentis Biomaterials RGNT Stock Holding History

AIGH Capital Management’s Portfolio RGNT Stock Details RGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-300,000	Closed	-$917K	–	61
2026 Q1	$917K	Buy	+300,000	New	+$1.44M	0.13%	39

Other funds holding RGNT

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

AIGH Capital Management's RGNT Position: Q2 2026 in Review

AIGH Capital Management sold out of Regentis Biomaterials (RGNT) in Q2 2026, closing a stake of 300,000 shares — an estimated $917K sold.

AIGH Capital Management first reported a position in RGNT in Q1 2026 and held it in 1 quarter. The position peaked at $917K in Q1 2026. 6 funds tracked by Wall St. Rank hold RGNT as of Q2 2026.

AIGH Capital Management reported no remaining Regentis Biomaterials position as of Q2 2026 after selling out during the quarter.
AIGH Capital Management sold 300,000 Regentis Biomaterials shares in Q2 2026, an estimated $917K.
AIGH Capital Management first reported a position in Regentis Biomaterials in Q1 2026 and held it in 1 quarter.
AIGH Capital Management's Regentis Biomaterials position peaked at $917K in Q1 2026.
6 funds tracked by Wall St. Rank held Regentis Biomaterials as of Q2 2026.

Based on AIGH Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.